CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

Metastatic Liver Cancer Outcomes Improved in Two Cases Using CureMatch-Recommended Therapy

Metastatic Liver Cancer Outcomes Improved in Two Cases Using CureMatch-Recommended Therapy
Case Studies

Two patients with metastatic liver cancers were treated with one or more lines of chemotherapy. Personalized combination therapy options were then suggested using a beta version of the CureMatch platform, leading to stabilization of the condition in both patients.

Case Study #1
A 62-year-old man diagnosed with BCLC (Barcelona Clinic liver cancer) stage B hepatocellular carcinoma (HCC) was initially treated with chemoembolization, but nevertheless developed metastatic disease. Despite subsequent treatment with sorafenib, the disease continued to progress. At this time, a personalized medicine approach was taken.

A liquid biopsy was taken of circulating tumor DNA in the blood, and next generation DNA-sequencing was performed (Guardant360®), revealing the CDKN2A R80* and CTNNB1 G34V genomic alterations.

The patient data was then inputted into the CureMatch platform, and a report was generated that ranked multiple options; the highest ranked option was personalized combination therapy using palbociclib (targeting CDKN2A R80*) and celecoxib (targeting CTNNB1 G34V). The oncologist selected this option, and started the patient on celecoxib. After 4 weeks, the level of des-gamma-carboxy prothrombin (DCP), a non-functional prothrombin which is generally regarded as an HCC biomarker, declined by 31%. Palbociclib was then initiated, and over the next 4 weeks, the level of DCP further declined a total of 84% from the baseline (Fig. 1).

Fig. 1. Des-gamma-carboxy prothrombin (DCP) levels in a patient with stage B HCC before and after treatment with drugs selected by CureMatch decision support. DCP levels were reduced by 84% after 4 weeks of combined therapy of palbociclib and celecoxib.

The patient’s condition stabilized as a result of the personalized treatment approach.

Case Study #2
A 64-year-old woman was diagnosed with BCLC stage A HCC and was treated with chemoembolization while awaiting a liver transplant. The patient received an orthotopic liver transplant and a year later was diagnosed with peritoneal carcinomatosis.

A personalized medicine approach was taken. Both a solid tumor biopsy of explanted liver tissue and a liquid biopsy of circulating tumor DNA in the blood were taken. DNA sequencing of the solid tissue biopsy was performed by Foundation Medicine, and DNA-sequencing of the liquid biopsy was performed by Guardant, with the combined tests revealing the MET Y501C missense mutation, the TP53 R273C missense mutation, and the PTEN L139* nonsense mutation.

The data from both tests were integrated and inputed into the CureMatch platform, and a report was generated that ranked multiple options; the highest ranked option was personalized combination therapy using cabozantinib (targeting MET Y501C directly and TP53 R273C indirectly) and sirolimus (targeting PTEN and also serving as an immunosuppressant due to transplantation). The patient initiated this personalized combination therapy, and within one month, the level of alpha fetoprotein (AFP) declined by 64% (Fig. 2). Declining levels of AFP are indicative of a lack of tumor growth.

Fig. 2. Levels of alpha fetoprotein (AFP) were reduced by 65% after one month of treatment with a combined therapy of cabozantinib and sirolimus. This combined therapy was selected with the assistance of the CureMatch decision support.

As a result of the personalized combination therapy, the patient’s condition stabilized.

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 859-2873

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data